1
|
Keiko Li H, Hasegawa S. Favorable tumor uptake and nuclear transport of Auger electrons by nuclear targeting with 111In-trastuzumab in an intraperitoneal tumor mouse model. Nucl Med Commun 2022; 43:763-769. [PMID: 35506286 DOI: 10.1097/mnm.0000000000001571] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVES The 111In-labeled anti-HER2 antibody trastuzumab modified with a nuclear-localizing sequence (NLS) peptide (111In-trastuzumab-NLS) is a radiopharmaceutical candidate for Auger electron radioimmunotherapy (AE-RIT). However, in-vivo action of 111In-trastuzumab-NLS is poorly understood in intraperitoneal tumors. We aimed to elucidate the nuclear targeting activity of 111In-trastuzumab-NLS in a mouse model of intraperitoneal tumors. METHODS Trastuzumab, trastuzumab-NLS-S with shorter NLS peptides, and trastuzumab-NLS-L with longer NLS peptides were tested in an intraperitoneal tumor xenograft. The AE-emitting radionuclide 111In was labeled with these antibodies. The cell-binding activity, nuclear importation, and cytotoxicity of those radiolabeled antibodies were examined in human cancer cell lines. Analyses of the biodistribution and in-vivo nuclear importation of 111In were conducted in a mouse model. RESULTS The two111In-trastuzumab-NLS variants delivered the radionuclide into the nucleus more efficiently and had a comparable cytotoxicity to 111In-trastuzumab against human gastric cancer cells, although had a lower cell binding affinity. 111In-trastuzumab-NLS-L exhibited both a superior tumor uptake and in vivo nuclear transportation of the radionuclide than 111In-trastuzumab. CONCLUSION Nuclear targeting using 111In-trastuzumab-NLS promotes a more efficient tumor cell uptake and subsequent nuclear translocation of the 111In AE-emitting radionuclide in vivo. This radio-immunoconjugate will likely be an effective agent for HER2-targeting by AE-RIT.
Collapse
Affiliation(s)
- Huizi Keiko Li
- Radiation and Cancer Biology Group, National Institutes for Quantum Science and Technology, Chiba, Japan
| | | |
Collapse
|
2
|
Qian LX, Yan L, Xu ZW, Shan LQ, Wang WT, He LM, He SM, Fan Y, Ge CY, Li HK, Hao DJ. [Early efficacy of three dimensional printed anatomical biomimetic cervical artificial disc replacement in the treatment of cervical degenerative diseases]. Zhonghua Wai Ke Za Zhi 2022; 60:223-229. [PMID: 35078297 DOI: 10.3760/cma.j.cn112139-20211202-00575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Objective: To investigate the efficacy and safety of a new cervical artificial disc prosthesis in the treatment of cervical degenerative diseases. Methods: The clinical data of 18 patients with single-level cervical degenerative diseases who underwent three dimensional printed anatomical bionic cervical disc replacement at Department of Spinal Surgery,Honghui Hospital,Xi'an Jiaotong University from May 2019 to July 2020 were analyzed retrospectively. There were 7 males and 11 females,aged (45±8) years old(range:28 to 58 years).The surgical segment was located at C3-4 level in 2 cases, C4-5 level in 5 cases, C5-6 level in 9 cases, and C6-7 level in 2 cases.The clinical and radiographic outcomes were recorded and compared at preoperative,postoperative times of one month and twelve months.The clinical assessments contained Japanese orthopedic association (JOA) score,neck disability index (NDI) and visual analogue scale (VAS).Imaging assessments included range of motion (ROM) of cervical spine, prosthesis subsidence and prosthesis anteroposterior migration.Repeated measurement variance analysis was used for comparison between groups,and paired t test was used for pairwise comparison. Results: All patients underwent the operation successfully and were followed up for more than 12 months.Compared with preoperative score,the JOA score,NDI and VAS were significantly improved after surgery (all P<0.01).There was no significant difference in postoperative ROM compared with 1-and 12-month preoperative ROM (t=1.570,P=0.135;t=1.744,P=0.099). The prosthesis subsidence was (0.29±0.13) mm (range: 0.18 to 0.50 mm) at 12-month postoperatively.The migration of prosthesis at 12-months postoperatively were (0.71±0.20) mm (range: 0.44 to 1.08 mm).There was no prosthesis subsidence or migration>2 mm at 12-month postoperatively. Conclusion: Three dimensional printed anatomical biomimetic cervical artificial disc replacement has a good early clinical effect in the treatment of cervical degenerative diseases, good mobility can be obtained while maintaining stability.
Collapse
Affiliation(s)
- L X Qian
- Department of Spinal Surgery,Honghui Hospital,Xi'an Jiaotong University,Xi'an 710054,China
| | - L Yan
- Department of Spinal Surgery,Honghui Hospital,Xi'an Jiaotong University,Xi'an 710054,China
| | - Z W Xu
- Department of Spinal Surgery,Honghui Hospital,Xi'an Jiaotong University,Xi'an 710054,China
| | - L Q Shan
- Department of Spinal Surgery,Honghui Hospital,Xi'an Jiaotong University,Xi'an 710054,China
| | - W T Wang
- Department of Spinal Surgery,Honghui Hospital,Xi'an Jiaotong University,Xi'an 710054,China
| | - L M He
- Department of Spinal Surgery,Honghui Hospital,Xi'an Jiaotong University,Xi'an 710054,China
| | - S M He
- Department of Spinal Surgery,Honghui Hospital,Xi'an Jiaotong University,Xi'an 710054,China
| | - Y Fan
- Department of Spinal Surgery,Honghui Hospital,Xi'an Jiaotong University,Xi'an 710054,China
| | - C Y Ge
- Department of Spinal Surgery,Honghui Hospital,Xi'an Jiaotong University,Xi'an 710054,China
| | - H K Li
- Department of Spinal Surgery,Honghui Hospital,Xi'an Jiaotong University,Xi'an 710054,China
| | - D J Hao
- Department of Spinal Surgery,Honghui Hospital,Xi'an Jiaotong University,Xi'an 710054,China
| |
Collapse
|
3
|
Li HK, Morokoshi Y, Kodaira S, Kusumoto T, Minegishi K, Kanda H, Nagatsu K, Hasegawa S. Utility of 211At-trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically-relevant Mouse Model. J Nucl Med 2021; 62:1468-1474. [PMID: 33547212 DOI: 10.2967/jnumed.120.249300] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2020] [Accepted: 01/13/2021] [Indexed: 02/06/2023] Open
Abstract
A liver metastasis from a primary gastric cancer (LMGC) is relatively common and results in an extremely poor prognosis due to a lack of effective therapeutics. We here demonstrate in a clinically-relevant mouse model that an α-radioimmunotherapy (α-RIT) approach with astatine-211-labeled-trastuzumab (211At-trastuzumab) has efficacy against LMGCs that are positive for human epidermal growth factor receptor 2 (HER2). Methods: 211At was produced in a cyclotron via a 209Bi (α, 2n) 211At reaction. 211At-trastuzumab was subsequently generated using a single-step labelling method. NCI-N87 cells (HER2-positive human GC cells) carrying a luciferase gene were intrasplenically transplanted into severe combined immunodeficiency mice to generate a HER2-positive LMGC model. A bio-distribution study was then conducted through the intravenous injection of 211At-trastuzumab (1 MBq) into these LMGC xenograft mice. In parallel with this experimental therapy, PBS, intact trastuzumab or 211At-non-specific human IgG (1MBq) were injected into control groups. The therapeutic efficacy was evaluated by monitoring tumor changes by chemiluminescence imaging. Monitoring of body weights, white blood cell counts, and serum markers of tissue damage were conducted at regular intervals. Microdosimetry using a CR39 plastic detector was also performed. Results: The biodistribution analysis revealed an increased uptake of 211At-trastuzumab in the metastasized tumors that reached approximately 12% of the injected dose per gram of tissue (%ID/g) at 24 hours. In contrast, its uptake to the surrounding liver was about 4%ID/g. The LMGCs in the mouse model reduced dramatically at 1 week after the single systemic injection of 211At-trastuzumab. No recurrences were observed in six of eight mice treated with this single injection and their survival time was significantly prolonged compared to the control groups, including the animals treated with 211At-non-specific antibodies. No severe toxicities or abnormalities in terms of body weight, white blood cell number, liver function, or kidney parameters were observed in the 211At-trastuzumab group. Microdosimetric studies further revealed that 211At-trastuzumab had been delivered at an 11.5- fold higher dose to the LMGC lesions compared to the normal liver. Conclusion: α-RIT with 211At-trastuzumab has considerable potential as an effective and safe therapeutic option for LMGC.
Collapse
Affiliation(s)
- Huizi Keiko Li
- National Institutes for Quantum and Radiological Science and Technology, Japan
| | - Yukie Morokoshi
- National Institutes for Quantum and Radiological Science and Technology, Japan
| | - Satoshi Kodaira
- National Institutes for Quantum and Radiological Science and Technology, Japan
| | - Tamon Kusumoto
- National Institutes for Quantum and Radiological Science and Technology, Japan
| | - Katsuyuki Minegishi
- National Institutes for Quantum and Radiological Science and Technology, Japan
| | | | - Kotaro Nagatsu
- National Institutes for Quantum and Radiological Science and Technology, Japan
| | - Sumitaka Hasegawa
- National Institutes for Quantum and Radiological Science and Technology, Japan
| |
Collapse
|
4
|
Hasegawa S, Li HK. Abstract 5343: Experimental targeted alpha-particle therapy against liver metastasis of HER2-positive gastric cancer in mice. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-5343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Gastric cancer (GC) is one of the common cancer type and a leading cause of cancer-related death worldwide. Liver metastasis of gastric cancer (LMGC) is often found in GC patients and a fatal condition that is hard to be cured. HER2 overexpression is detected in a subset of about 10-20% of GC. HER2-targeting antibody trastuzumab has been used clinically for the treatment against advanced GC positive for HER2. Recently, targeted alpha-particle therapy has emerged as a new therapeutic option of cancer. Radionuclide astatine-211 is produced by cyclotron and emits alpha-particle at its decay with about 7 hours-half-life. Alpha-particle beam induces irreparable DNA damages to kill the cells. Here we investigated the therapeutic efficacy and toxicities of At-211-armed trastuzumab in a mouse model of LMGC positive for HER2. Trastuzumab was conjugated with At-211 to produce alpha-emitting antibodies targeting HER2 ([At-211]-trastuzumab). To generate a mouse LMGC model, we injected luciferase-labelled HER2-positive human metastatic NCI-N87 GC cells into splenic vein of severe combined immunodeficiency mice. Bio-distribution data showed that the maximum uptake of [At-211]trastuzumab in the liver metastatic GC tumors was approximately 12% of injected dose per tissue gram at 24 hours after injection. [At-211]trastuzumab was excreted mostly in the urine. For experimental therapeutics, a single dose of systemic injection of [At-211]trastuzumab (1 MBq) significantly reduced a tumor burden in the liver to extend the survival of model mice significantly compared to controls. Transient leukocytopenia was observed in mice received 1 MBq of [At-211]trastuzumab at 5-7 days after injection. No body weight loss was so far found in the mice treated with [At-211]trastuzumab. No Biochemical abnormalities for Liver and kidney function were found. These data suggest that targeted alpha-particle therapy using [At-211]trastuzumab is effective for LMGC.
Citation Format: Sumitaka Hasegawa, Huizi Keiko Li. Experimental targeted alpha-particle therapy against liver metastasis of HER2-positive gastric cancer in mice [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5343.
Collapse
|
5
|
Xie L, Hanyu M, Fujinaga M, Zhang Y, Hu K, Minegishi K, Jiang C, Kurosawa F, Morokoshi Y, Li HK, Hasegawa S, Nagatsu K, Zhang MR. 131I-IITM and 211At-AITM: Two Novel Small-Molecule Radiopharmaceuticals Targeting Oncoprotein Metabotropic Glutamate Receptor 1. J Nucl Med 2019; 61:242-248. [PMID: 31451486 DOI: 10.2967/jnumed.119.230946] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Accepted: 07/31/2019] [Indexed: 11/16/2022] Open
Abstract
Targeted radionuclide therapy (TRT) targeting oncoproteins facilitates the delivery of therapeutic radionuclides to tumor tissues with high precision. Herein, we developed 2 new radiopharmaceuticals, 4-131I-iodo- and 4-211At-astato-N-[4-(6-(isopropylamino)pyridine-4-yl)-1,3-thiazol-2-yl]-N-methylbenzamide (131I-IITM and 211At-AITM), targeting the ectopic metabotropic glutamate receptor 1 (mGluR1) in melanomas for TRT studies. Methods: 131I-IITM and 211At-AITM were synthesized by reacting a stannyl precursor with 131I-NaI and 211At in the presence of an oxidizing agent. The therapeutic efficacy and safety of the 2 radiopharmaceuticals were investigated using mGluR1-expressing B16F10 melanoma cells and melanoma-bearing mice. Results: 131I-IITM and 211At-AITM were obtained with a radiochemical purity of greater than 99% and radiochemical yields of 42.7% ± 10.4% and 45.7% ± 6.5%, respectively, based on the total radioactivity of used radionuclides. 131I-IITM and 211At-AITM exhibited a maximum uptake of 4.66% ± 0.70 and 7.68% ± 0.71 percentage injected dose per gram (%ID/g) in the targeted melanomas, respectively, and were rapidly cleared from nontarget organs after intravenous injection. Both agents markedly inhibited melanoma growth compared with the controls (61.00% and 95.68%, respectively). In the melanoma model, considerably greater therapeutic efficacy with negligible toxicity was observed using 211At-AITM. Conclusion: The nontoxic radiopharmaceuticals 131I-IITM and 211At-AITM are useful high-precision TRT agents that can be used to target the oncoprotein mGluR1 for melanoma therapy.
Collapse
Affiliation(s)
- Lin Xie
- Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Masayuki Hanyu
- Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Masayuki Fujinaga
- Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Yiding Zhang
- Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Kuan Hu
- Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Katsuyuki Minegishi
- Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Cuiping Jiang
- Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Fuki Kurosawa
- Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.,Department of Charged Particle Therapy Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; and
| | - Yukie Morokoshi
- Department of Charged Particle Therapy Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; and
| | - Huizi Keiko Li
- Department of Charged Particle Therapy Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; and.,The Japan Society for the Promotion of Science, Tokyo, Japan
| | - Sumitaka Hasegawa
- Department of Charged Particle Therapy Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; and
| | - Kotaro Nagatsu
- Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Ming-Rong Zhang
- Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| |
Collapse
|
6
|
Kodaira S, Morokoshi Y, Li HK, Konishi T, Kurano M, Hasegawa S. Evidence of Local Concentration of α-Particles from 211At-Labeled Antibodies in Liver Metastasis Tissue. J Nucl Med 2019; 60:497-501. [PMID: 30291193 PMCID: PMC6448461 DOI: 10.2967/jnumed.118.216853] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2018] [Accepted: 09/05/2018] [Indexed: 12/12/2022] Open
Abstract
We investigated the local concentration of α-particles from 211At-labeled trastuzumab antibodies against human epidermal growth factor receptor type 2 antigens in liver metastasis tissue of mice. Methods: Mice carrying metastatic cancer in their liver were injected with 211At-agent. After 12 h, the liver was removed and sliced, and 2 tissue samples of liver tissues without lesions and one containing metastatic lesions were mounted on the CR-39 plastic nuclear track detector. Microscope images of the tissues on the CR-39 were acquired. After irradiation for 31 h, the tissues were removed from the CR-39. A microscope image of α-particle tracks on the CR-39 was acquired after chemical etching. The positions of each tissue sample and the emitted α-particle tracks were adjusted to the same coordinates. Results: The positional distribution of α-particle tracks emitted from 211At was consistent within the tissue. The α-particle tracks were mainly allocated in the tumor region of the tissue. The absorbed dose in individual cells segmented by 10-μm intervals was obtained by the spectroscopic analysis of the linear-energy-transfer spectrum. The concentration efficiency-the track density ratio of α-particle tracks in the necrotized tissue, which was the tumor region, to the normal tissue-was found to be 6.0 ± 0.2. In the tumor region, the high-linear-energy-transfer α-particles deposited a large enough dose to cause lethal damage to the cancer cells. Conclusion: The total absorbed dose ranged from 1 to 7 Gy with a peak at around 2 Gy, which would correspond to a 2-3 times higher biologically equivalent dose because of the high relative biological effectiveness of the α-particles emitted from 211At.
Collapse
Affiliation(s)
- Satoshi Kodaira
- Radiation Measurement Research Team, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Yukie Morokoshi
- Radiation and Cancer Biology Team, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; and
| | - Huizi Keiko Li
- Radiation and Cancer Biology Team, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; and
| | - Teruaki Konishi
- Regenerative Therapy Research Team, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Mieko Kurano
- Radiation Measurement Research Team, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Sumitaka Hasegawa
- Radiation and Cancer Biology Team, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; and
| |
Collapse
|
7
|
Hasegawa S, Keiko Li H. Alpha-radioimmunotherapy Against Liver Metastasis of HER2-positive Gastric Cancer in a Mouse Model. J Med Imaging Radiat Sci 2019. [DOI: 10.1016/j.jmir.2019.03.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
8
|
Li HK, Hasegawa S. Abstract 860: Experimental alpha-radioimmunotherapy for liver metastasis of gastric cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Gastric cancer (GC) is one of the leading causes of cancer-related death worldwide. Early stage of GC is curable by surgical therapy or endoscopic surgery. However, previous studies reported that 35% of patients is present with evidence of distant metastasis at the time of diagnosis of GC. Metastatic GC is fetal and the patients with metastatic GC has extremely poor prognosis because current therapeutic approaches to metastatic GC are still limited. Therefore, the development of new therapeutic options has been eagerly awaited. Liver metastasis of GC (LMGC) is often observed during GC progression. It has been shown that 4-14% of the patients has LMGC. It is believed that LMGC is occurred by blood-borne metastasis of GC cells via blood stream. A previous study reported that approximately 70% of LMGC was positive for human epidermal growth factor receptor 2 (HER2). Therefore, HER2 may be a reliable therapeutic target for LMGC. Alpha-particle radioimmunotherapy (alpha-RIT) is an emerging new therapy, in which radioisotopes emitting cytotoxic alpha-particle radiation are delivered to target cancer cells to kill the cells by target-specific antibody. Among alpha-particle emitters, astatine-211 (At-211) is a promising emitter because it emits highly cytotoxic alpha-particles during its decay process with a half-life of 7.2 hours. The aim of this study is to evaluate the therapeutic efficacy and toxicity of At-211-labled anti-HER2 antibody trastuzumab ([At-211]trastuzumab) in a preclinical mouse model of HER2-positive LMGC. We established a mouse model of LMGC by injection of luciferase-labelled HER2-positive human metastatic GC cells (NCI-N87) into splenic vein of severe combined immunodeficiency mouse. Biodistribution studies revealed that the maximum tumor uptake of [At-211]trastuzumab was about 12% of injected dose per tissue gram 24 hours after injection. In experimental therapies, a systemic injection of [At-211]trastuzumab (1 MBq) significantly reduced a tumor burden in the liver and prolonged the survival. Transient but recoverable leukocytopenia was observed in mice received 1 MBq of [At-211]trastuzumab at 5-7 days after injection. No body weight loss was found during the observation period. In this study, we provides a preclinical evidence that alpha-RIT using [At-211]trastuzumab may be a new therapeutic option against LMGC.
Citation Format: Huizi Keiko Li, Sumitaka Hasegawa. Experimental alpha-radioimmunotherapy for liver metastasis of gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 860.
Collapse
Affiliation(s)
- Huizi Keiko Li
- 1National Institutes for Quantum and Radiological Science and Technology, Japan Society for Promotion Science, Japan
| | - Sumitaka Hasegawa
- 2National Institutes for Quantum and Radiological Science and Technology, Japan
| |
Collapse
|
9
|
Li HK, Sugyo A, Tsuji AB, Morokoshi Y, Minegishi K, Nagatsu K, Kanda H, Harada Y, Nagayama S, Katagiri T, Nakamura Y, Higashi T, Hasegawa S. α-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10. Cancer Sci 2018; 109:2302-2309. [PMID: 29952132 PMCID: PMC6029834 DOI: 10.1111/cas.13636] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2018] [Revised: 04/17/2018] [Accepted: 05/02/2018] [Indexed: 11/28/2022] Open
Abstract
Synovial sarcoma (SS) is a rare yet refractory soft‐tissue sarcoma that predominantly affects young adults. We show in a mouse model that radioimmunotherapy (RIT) with an α‐particle emitting anti‐Frizzled homolog 10 (FZD10) antibody, synthesized using the α‐emitter radionuclide astatine‐211 (211At‐OTSA101), suppresses the growth of SS xenografts more efficiently than the corresponding β‐particle emitting anti‐FZD10 antibody conjugated with the β‐emitter yettrium‐90 (90Y‐OTSA101). In biodistribution analysis, 211At was increased in the SS xenografts but decreased in other tissues up to 1 day after injection as time proceeded, albeit with a relatively higher uptake in the stomach. Single 211At‐OTSA101 doses of 25 and 50 μCi significantly suppressed SS tumor growth in vivo, whereas a 50‐μCi dose of 90Y‐OTSA101 was needed to achieve this. Importantly, 50 μCi of 211At‐OTSA101 suppressed tumor growth immediately after injection, whereas this effect required several days in the case of 90Y‐OTSA101. Both radiolabeled antibodies at the 50‐μCi dosage level significantly prolonged survival. Histopathologically, severe cellular damage accompanied by massive cell death was evident in the SS xenografts at even 1 day after the 211At‐OTSA101 injection, but these effects were relatively milder with 90Y‐OTSA101 at the same timepoint, even though the absorbed doses were comparable (3.3 and 3.0 Gy, respectively). We conclude that α‐particle RIT with 211At‐OTSA101 is a potential new therapeutic option for SS.
Collapse
Affiliation(s)
- Huizi Keiko Li
- Radiation and Cancer Biology Team, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.,Graduate School of Medical and Pharmaceutical Sciences, Chiba University, Chiba, Japan.,Japan Society for the Promotion of Science, Tokyo, Japan
| | - Aya Sugyo
- Department of Molecular Imaging and Theranostics, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Atsushi B Tsuji
- Department of Molecular Imaging and Theranostics, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Yukie Morokoshi
- Radiation and Cancer Biology Team, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Katsuyuki Minegishi
- Targetry and Target Chemistry Team, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Kotaro Nagatsu
- Targetry and Target Chemistry Team, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Hiroaki Kanda
- Department of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan
| | | | - Satoshi Nagayama
- Department of Gastroenterological Surgery, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - Toyomasa Katagiri
- Division of Genome Medicine, Institute for Genome Research, Tokushima University, Tokushima, Japan
| | - Yusuke Nakamura
- Department of Medicine, The University of Chicago, Chicago, IL, USA
| | - Tatsuya Higashi
- Department of Molecular Imaging and Theranostics, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Sumitaka Hasegawa
- Radiation and Cancer Biology Team, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| |
Collapse
|
10
|
Bai N, Yang LF, An LH, Wang W, Li YQ, Sheng Y, Wang T, Li HK, Yuan L. [Dynamic visual analysis of neutrophils chemotaxis in peritoneal cavity of schizophrenic model in mice]. Beijing Da Xue Xue Bao Yi Xue Ban 2018; 50:226-230. [PMID: 29643519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
OBJECTIVE To compare the differences of neutrophils chemotaxis ability in peritoneal cavity between normal rats and schizopherenic rats with cell dynamic visualization system. METHODS In the study,18 healthy Kunming rats were randomly divided into 3 groups which were control group (n=6), 0.3 mg/kg MK-801 treatment group (n=6), 0.6 mg/kg dizocilpine maleate (MK-801) treatment group(n=6), extracted neutrophils separately, and observed the morphology and counted under a microscope. Each group of cells was divided into two parts for chemotactic experiment, called chemokine agent treatment group and no chemokine agent treatment group respectively, indicating control 1, 0.3 mg/kg MK-801 treatment 1,0.6 mg/kg MK-801 treatment 1 and control 2, 0.3 mg/kg MK-801 treatment 2,0.6 mg/kg MK-801 treatment 2. The dynamic migration of cells was recorded using the NIS-Elements software, and TAXIScan Analyzer 2 software was used to select 30 cells (n=30) in each group of cells and analyze cells migration trajectory, speed and distance, and use pair test and One-Way analysis of variance for statistical analysis. RESULTS The number of neutrophils in control group, 0.3 mg/kg MK-801 treatment group and 0.6 mg/kg MK-801 treatment group were(1.00±0.03)×104/mL,(0.05±0.02)×104/mL,(0.32±0.01)×104/mL respectively, the differences of results were statistically significant(P<0.05).Under the effect of chemotactic agent,the directional migration capability of neutrophils in control group 1, 0.3 mg/kg MK-801 treatment group 1 and 0.6 mg/kg MK-801 treatment group 1 were(0.85±0.11) radian,(1.00±0.11) radian,(0.96±0.10) radian respectively (P<0.05); the migration velocities of neutrophils were (0.09±0.02) μm/s,(0.12±0.01) μm/s,(0.14±0.01) μm/s respectively (P<0.05);the migration distances of neutrophils were (94.26±0.02) μm,(134.61±0.01) μm,(156.19±0.01) μm respectively(P<0.05). CONCLUSION Compared with neutrophils in peritoneal cavity of control group, the neutrophils in peritoneal cavity of schizophrenic rats have stronger chemotactic movement ability.
Collapse
Affiliation(s)
- N Bai
- Department of Pharmceutical,Jinzhou Medical University, Jinzhou 121000, Liaoning, China;Peking University Medical and Health Analysis Center,Beijing 100191,China
| | - L F Yang
- Peking University Medical and Health Analysis Center,Beijing 100191,China;Department of Chemical Biology,Peking University School of Parmaceutical Sciences,Beijing 100191,China
| | - L H An
- Peking University Medical and Health Analysis Center,Beijing 100191,China
| | - W Wang
- Peking University Medical and Health Analysis Center,Beijing 100191,China
| | - Y Q Li
- Peking University Medical and Health Analysis Center,Beijing 100191,China;Department of Chemical Biology,Peking University School of Parmaceutical Sciences,Beijing 100191,China
| | - Y Sheng
- Peking University Medical and Health Analysis Center,Beijing 100191,China;Department of Chemical Biology,Peking University School of Parmaceutical Sciences,Beijing 100191,China
| | - T Wang
- Peking University Medical and Health Analysis Center,Beijing 100191,China;Department of Chemical Biology,Peking University School of Parmaceutical Sciences,Beijing 100191,China
| | - H K Li
- Department of Basic Science, Jinzhou Medical University, Jinzhou 121000, Liaoning, China
| | - L Yuan
- Peking University Medical and Health Analysis Center,Beijing 100191,China;Department of Chemical Biology,Peking University School of Parmaceutical Sciences,Beijing 100191,China
| |
Collapse
|
11
|
Kodaira S, Li HK, Konishi T, Kitamura H, Kurano M, Hasegawa S. Validating α-particle emission from 211At-labeled antibodies in single cells for cancer radioimmunotherapy using CR-39 plastic nuclear track detectors. PLoS One 2017; 12:e0178472. [PMID: 28658304 PMCID: PMC5489156 DOI: 10.1371/journal.pone.0178472] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2016] [Accepted: 05/13/2017] [Indexed: 11/18/2022] Open
Abstract
Recently, 211At has received increasing attention as a potential radionuclide for cancer radioimmunotherapy. It is a α-particle emitter, which is extremely effective against malignant cells. We demonstrate a method to verify the efficiency of 211At-labeled trastuzumab antibodies (211At-trastuzumab) against HER2 antigens, which has not been determined for radioimmunotherapy. A CR-39 plastic nuclear detector is used for measuring the position and the linear energy transfer (LET) of individual 211At α- particle tracks. The tracks and 211At-trastuzumab-binding cells were co-visualized by using the geometric information recorded on the CR-39. HER2-positive human gastric cancer cells (NCI-N87), labelled with 211At-trastuzumab, were dropped on the centre of the CR-39 plate. Microscope images of the cells and the corresponding α-tracks acquired by position matching were obtained. In addition, 3.5 cm × 3.5 cm macroscopic images of the whole plate were acquired. The distribution of number of α-particles emitted from single cells suggests that 80% of the 211At-trastuzumab-binding cells emitted α-particles. It also indicates that the α-particles may strike the cells several times along their path. The track-averaged LET of the α-particles is evaluated to be 131 keV/μm. These results will enable quantitative evaluation of delivered doses to target cells, and will be useful for the in vitro assessment of 211At-based radioimmunotherapeutic agents.
Collapse
Affiliation(s)
- Satoshi Kodaira
- Radiation Measurement Research Team, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
- * E-mail:
| | - Huizi Keiko Li
- Radiation and Cancer Biology Team, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
- JSPS Research Fellow, Graduate School of Medical and Pharmaceutical Sciences, Chiba University, Chiba, Japan
| | - Teruaki Konishi
- Regenerative Therapy Research Team, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Hisashi Kitamura
- Radiation Measurement Research Team, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Mieko Kurano
- Radiation Measurement Research Team, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Sumitaka Hasegawa
- Radiation and Cancer Biology Team, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| |
Collapse
|
12
|
Li HK, Morokoshi Y, Nagatsu K, Kamada T, Hasegawa S. Locoregional therapy with α-emitting trastuzumab against peritoneal metastasis of human epidermal growth factor receptor 2-positive gastric cancer in mice. Cancer Sci 2017; 108:1648-1656. [PMID: 28514062 PMCID: PMC5543454 DOI: 10.1111/cas.13282] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2017] [Revised: 05/09/2017] [Accepted: 05/13/2017] [Indexed: 12/28/2022] Open
Abstract
Peritoneal metastasis of gastric cancer (PMGC) is incurable and thus has an extremely poor prognosis. We have found, however, that locoregionally administered trastuzumab armed with astatine‐211 (211At‐trastuzumab) is effective against human epidermal growth factor receptor 2 (HER2)‐positive PMGC in a xenograft mouse model. We first observed that 211At‐trastuzumab can specifically bind and effectively kill NCI‐N87 (N87) cells, which are HER2‐positive human metastatic GC cells, both in vitro and in s.c. tumors. We established a PMGC mouse model using N87 xenografts stably expressing luciferase to test α‐particle radioimmunotherapy with 211At‐trastuzumab against PMGC. Biodistribution analysis in this PMGC mouse model revealed that the i.p. administration of 211At‐trastuzumab (1 MBq) was a more efficient means of delivery of 211At into metastatic tumors than i.v. injection; the maximum tumor uptake with i.p. administration was over 60% injected dose per gram of tissue (%ID/g) compared to approximately 18%ID/g with i.v. injection. Surprisingly, a single i.p. injection of 211At‐trastuzumab (1 MBq) was sufficient to completely eradicate intraperitoneally disseminated HER2‐positive GC xenografts in two of six treated mice by inducing DNA double‐strand breaks, and to drastically reduce the tumor burden in another three mice. No bodyweight loss, leukocytopenia, or significant biochemical changes in liver or kidney function were observed in the treatment group. Accordingly, locoregionally administered 211At‐trastuzumab significantly prolonged the survival time of HER2‐positive PMGC mice compared with control treatments. Our results provide a proof‐of‐concept demonstration that locoregional therapy with 211At‐trastuzumab may offer a new treatment option for HER2‐positive PMGC.
Collapse
Affiliation(s)
- Huizi Keiko Li
- Radiation and Cancer Biology Team, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.,Graduate School of Medical and Pharmaceutical Sciences, Chiba University, Chiba, Japan.,Japan Society for the Promotion of Science, Tokyo, Japan
| | - Yukie Morokoshi
- Radiation and Cancer Biology Team, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Kotaro Nagatsu
- Targetry and Target Chemistry Team, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Tadashi Kamada
- Graduate School of Medical and Pharmaceutical Sciences, Chiba University, Chiba, Japan.,Clinical Research Cluster, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Sumitaka Hasegawa
- Radiation and Cancer Biology Team, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| |
Collapse
|
13
|
Abstract
The human brain is an extremely complex system of 1010-1011 neurons. To construct brain-like neuromorphic hardware, the neuron unit should be implemented effectively. Here, we report a neuron transistor based on a MoS2 flake, which has summation and threshold functions similar to biological neurons and may act as a basic neuron unit in neuromorphic hardware. The neuron transistor is composed of a floating gate and two control gates. A heavily doped silicon substrate serves as the floating gate, while the two control gates are capacitively coupled with the floating gate. The neuron transistor can be well controlled by the two control gates individually or simultaneously. The drain current can be modulated by the input voltages at the control gates. While the current response of the neuron transistor has a large dependence on the magnitude of the input signal, it shows little dependence on the frequency of the input signal. To demonstrate the potential neuromorphic application of the neuron transistor, functions including abacus-like function, AND logic and OR logic are realized in the neuron transistor.
Collapse
Affiliation(s)
- S G Hu
- State Key Laboratory of Electronic Thin Films and Integrated Devices, University of Electronic Science and Technology of China, Chengdu 610054, People's Republic of China
| | | | | | | | | | | |
Collapse
|
14
|
Lee Y, Li HK, Masaoka A, Sunada S, Hirakawa H, Fujimori A, Nickoloff JA, Okayasu R. The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining. Radiother Oncol 2016; 121:162-168. [PMID: 27666928 DOI: 10.1016/j.radonc.2016.08.029] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2016] [Revised: 08/31/2016] [Accepted: 08/31/2016] [Indexed: 01/27/2023]
Abstract
BACKGROUND AND PURPOSE PU-H71 is a purine-scaffold Hsp90 inhibitor developed to overcome limitations of conventional Hsp90 inhibitors. This study was designed to investigate the combined effect of PU-H71 and heavy ion irradiation on human tumor and normal cells. MATERIALS AND METHODS The effects of PU-H71 were determined by monitoring cell survival by colony formation, and DNA double-strand break (DSB) repair by γ-H2AX foci and immuno-blotting DSB repair proteins. The mode of cell death was evaluated by sub-G1 DNA content (as an indicator for apoptosis), and mitotic catastrophe. RESULTS PU-H71 enhanced heavy ion irradiation-induced cell death in three human cancer cell lines, but the drug did not radiosensitize normal human fibroblasts. In irradiated tumor cells, PU-H71 increased the persistence of γ-H2AX foci, and it reduced RAD51 foci and phosphorylated DNA-PKcs, key DSB repair proteins involved in homologous recombination (HR) and non-homologous end joining (NHEJ). In some tumor cell lines, PU-H71 altered the sub-G1 cell fraction and mitotic catastrophe following carbon ion irradiation. CONCLUSION Our results demonstrate that PU-H71 sensitizes human cancer cells to heavy ion irradiation by inhibiting both HR and NHEJ DSB repair pathways. PU-H71 holds promise as a radiosensitizer for enhancing the efficacy of heavy ion radiotherapy.
Collapse
Affiliation(s)
- Younghyun Lee
- Dept. of Basic Medical Sciences for Radiation Damages, National Institute of Radiological Sciences, Chiba, Japan
| | - Huizi Keiko Li
- Dept. of Basic Medical Sciences for Radiation Damages, National Institute of Radiological Sciences, Chiba, Japan; Graduate School of Medical and Pharmaceutical Sciences, Chiba University, Japan
| | - Aya Masaoka
- Dept. of Basic Medical Sciences for Radiation Damages, National Institute of Radiological Sciences, Chiba, Japan
| | - Shigeaki Sunada
- Dept. of Basic Medical Sciences for Radiation Damages, National Institute of Radiological Sciences, Chiba, Japan; Department of Nuclear Engineering and Management, School of Engineering, The University of Tokyo, Japan
| | - Hirokazu Hirakawa
- Dept. of Basic Medical Sciences for Radiation Damages, National Institute of Radiological Sciences, Chiba, Japan
| | - Akira Fujimori
- Dept. of Basic Medical Sciences for Radiation Damages, National Institute of Radiological Sciences, Chiba, Japan
| | - Jac A Nickoloff
- Department of Environmental and Radiological Health Sciences, Colorado State University, USA
| | - Ryuichi Okayasu
- Dept. of Basic Medical Sciences for Radiation Damages, National Institute of Radiological Sciences, Chiba, Japan.
| |
Collapse
|
15
|
Li HK, Matsumoto Y, Furusawa Y, Kamada T. PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy. J Radiat Res 2016; 57:572-575. [PMID: 27242340 PMCID: PMC5045081 DOI: 10.1093/jrr/rrw054] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/03/2016] [Revised: 03/16/2016] [Accepted: 04/03/2016] [Indexed: 06/05/2023]
Abstract
PU-H71, a heat shock protein 90 (Hsp90) inhibitor, has yielded therapeutic efficacy in many preclinical models and is currently in clinical trials. Carbon-ion radiotherapy (CIRT) has provided successful tumor control; however, there is still room for improvement, particularly in terms of tumor-specific radiosensitization. The Hsp90 inhibitor PU-H71 has been shown to sensitize tumor cells to X-ray radiation. A murine osteosarcoma cell line (LM8) and a normal human fibroblast cell line (AG01522) were treated with PU-H71 before X-ray, 14- or 50-keV/µm carbon-ion beam (C-ion) irradiation. Cell survival and protein expression were evaluated with colony formation and western blot, respectively. Treatment with PU-H71 alone was shown to be non-toxic to both cell lines; however, PU-H71 was shown to significantly sensitize LM8 cells to not only X-ray, but also to C-ion irradiation, while only a minimal sensitizing effect was observed in AG01522 cells. PU-H71 treatment was found to suppress the protein expression levels of Rad51 and Ku70, which are associated with the homologous recombination pathway and the non-homologous end-joining pathway of double-strand break repair. The findings reported here suggest that PU-H71 could be a promising radiosensitizer for CIRT.
Collapse
Affiliation(s)
- Huizi Keiko Li
- Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage, Chiba 263-8555, Japan Molecular Imaging Center, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage, Chiba 263-8555, Japan Graduate School of Medical and Pharmaceutical Sciences, Chiba University, 1-8-1, Inohana, Chuo, Chiba 263-8522, Japan
| | - Yoshitaka Matsumoto
- Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage, Chiba 263-8555, Japan Proton Medical Research Center, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8576, Japan
| | - Yoshiya Furusawa
- Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage, Chiba 263-8555, Japan
| | - Tadashi Kamada
- Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage, Chiba 263-8555, Japan Graduate School of Medical and Pharmaceutical Sciences, Chiba University, 1-8-1, Inohana, Chuo, Chiba 263-8522, Japan
| |
Collapse
|
16
|
Li HK, Morokoshi Y, Daino K, Furukawa T, Kamada T, Saga T, Hasegawa S. Transcriptomic Signatures of Auger Electron Radioimmunotherapy Using Nuclear Targeting (111)In-Trastuzumab for Potential Combination Therapies. Cancer Biother Radiopharm 2016; 30:349-58. [PMID: 26447839 DOI: 10.1089/cbr.2015.1882] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
(111)In-labeled trastuzumab modified with nuclear localizing signal (NLS) peptides ((111)In-trastuzumab-NLS) efficiently delivers an Auger electron (AE) emitter (111)In into the cell nucleus and is thus a promising radiopharmaceutical in AE radioimmunotherapy (AE-RIT) for targeted killing of HER2-positive cancer. However, further improvement of its therapeutic efficacy is required. In this study, the authors show a transcriptomic approach to identify potential targets for enhancing the cytotoxic effects of (111)In-trastuzumab-NLS. They generated two types of (111)In-trastuzumab-NLS harboring different numbers of NLS peptides, (111)In-trastuzumab-NLS-S and -L. These radioimmunoconjugates (230 and 460 kBq) showed a significant higher cytotoxicity to SKBR3 human breast cancer cells overexpressing HER2 compared to (111)In-trastuzumab. Microarray analysis revealed that NF-kB-related genes (38 genes) were significantly changed in transcription by (111)In trastuzumab-NLS-L (230 kBq) treatment. Quantitative reverse transcription polymerase chain reaction confirmed the microarray data by showing transcriptional alternation of selected NF-κB target genes in cells treated with (111)In-trastuzumab-NLS-L. Interestingly, bortezomib, a drug known as a NF-κB modulator, significantly enhanced the cytotoxicity of (111)In-trastuzumab-NLS-L in SKBR3 cells. Taken together, the transcriptome data suggest the possibility that the modulation of NF-kB signaling activity is a molecular signature of (111)In-trastuzumab-NLS and coadministration of bortezomib may be efficacious in enhancement of AE-RIT with (111)In-trastuzumab-NLS.
Collapse
Affiliation(s)
- Huizi Keiko Li
- 1 Molecular Imaging Center, National Institute of Radiological Sciences , Chiba, Japan .,2 Graduate School of Medical and Pharmaceutical Sciences, Chiba University , Chiba, Japan .,3 Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan
| | - Yukie Morokoshi
- 1 Molecular Imaging Center, National Institute of Radiological Sciences , Chiba, Japan
| | - Kazuhiro Daino
- 4 Research Center for Radiation Protection, National Institute of Radiological Sciences, Chiba, Japan
| | - Takako Furukawa
- 1 Molecular Imaging Center, National Institute of Radiological Sciences , Chiba, Japan
| | - Tadashi Kamada
- 2 Graduate School of Medical and Pharmaceutical Sciences, Chiba University , Chiba, Japan .,3 Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan
| | - Tsuneo Saga
- 1 Molecular Imaging Center, National Institute of Radiological Sciences , Chiba, Japan
| | - Sumitaka Hasegawa
- 1 Molecular Imaging Center, National Institute of Radiological Sciences , Chiba, Japan
| |
Collapse
|
17
|
Li HK, Chen TP, Hu SG, Li XD, Liu Y, Lee PS, Wang XP, Li HY, Lo GQ. Highly spectrum-selective ultraviolet photodetector based on p-NiO/n-IGZO thin film heterojunction structure. Opt Express 2015; 23:27683-27689. [PMID: 26480430 DOI: 10.1364/oe.23.027683] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Ultraviolet photodetector with p-n heterojunction is fabricated by magnetron sputtering deposition of n-type indium gallium zinc oxide (n-IGZO) and p-type nickel oxide (p-NiO) thin films on ITO glass. The performance of the photodetector is largely affected by the conductivity of the p-NiO thin film, which can be controlled by varying the oxygen partial pressure during the deposition of the p-NiO thin film. A highly spectrum-selective ultraviolet photodetector has been achieved with the p-NiO layer with a high conductivity. The results can be explained in terms of the "optically-filtering" function of the NiO layer.
Collapse
|
18
|
Harding V, Fenu E, Medani H, Shaboodien R, Ngan S, Li HK, Burt R, Diamantis N, Tuthill M, Blagden S, Gabra H, Urch CE, Moser S, Agarwal R. Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer. Br J Cancer 2012; 107:925-30. [PMID: 22878372 PMCID: PMC3464770 DOI: 10.1038/bjc.2012.343] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2012] [Revised: 06/24/2012] [Accepted: 06/26/2012] [Indexed: 01/27/2023] Open
Abstract
BACKGROUND Paracentesis for malignant ascites is usually performed as an in-patient procedure, with a median length of stay (LoS) of 3-5 days, with intermittent clamping of the drain due to a perceived risk of hypotension. In this study, we assessed the safety of free drainage and the feasibility and cost-effectiveness of daycase paracentesis. METHOD Ovarian cancer admissions at Hammersmith Hospital between July and October 2009 were audited (Stage 1). A total of 21 patients (Stage 2) subsequently underwent paracentesis with free drainage of ascites without intermittent clamping (October 2010-January 2011). Finally, 13 patients (19 paracenteses, Stage 3), were drained as a daycase (May-December 2011). RESULTS Of 67 patients (Stage 1), 22% of admissions and 18% of bed-days were for paracentesis, with a median LoS of 4 days. In all, 81% of patients (Stage 2) drained completely without hypotension. Of four patients with hypotension, none was tachycardic or symptomatic. Daycase paracentesis achieved complete ascites drainage without complications, or the need for in-patient admission in 94.7% of cases (Stage 3), and cost £954 compared with £1473 for in-patient drainage. CONCLUSIONS Free drainage of malignant ascites is safe. Daycase paracentesis is feasible, cost-effective and reduces hospital admissions, and potentially represents the standard of care for patients with malignant ascites.
Collapse
Affiliation(s)
- V Harding
- Department of Oncology, Hammersmith Hospital Campus, Imperial College London, Du Cane Road, London W12 0NN, UK
| | - E Fenu
- National Clinical Guideline Centre, Royal College of Physicians, London NW1 4L, UK
| | - H Medani
- Department of Oncology, Hammersmith Hospital Campus, Imperial College London, Du Cane Road, London W12 0NN, UK
| | - R Shaboodien
- Department of Oncology, Hammersmith Hospital Campus, Imperial College London, Du Cane Road, London W12 0NN, UK
| | - S Ngan
- Department of Oncology, Hammersmith Hospital Campus, Imperial College London, Du Cane Road, London W12 0NN, UK
| | - H K Li
- Department of Oncology, Hammersmith Hospital Campus, Imperial College London, Du Cane Road, London W12 0NN, UK
| | - R Burt
- Department of Oncology, Hammersmith Hospital Campus, Imperial College London, Du Cane Road, London W12 0NN, UK
| | - N Diamantis
- Department of Oncology, Hammersmith Hospital Campus, Imperial College London, Du Cane Road, London W12 0NN, UK
| | - M Tuthill
- Department of Oncology, Hammersmith Hospital Campus, Imperial College London, Du Cane Road, London W12 0NN, UK
| | - S Blagden
- Department of Oncology, Hammersmith Hospital Campus, Imperial College London, Du Cane Road, London W12 0NN, UK
| | - H Gabra
- Department of Oncology, Hammersmith Hospital Campus, Imperial College London, Du Cane Road, London W12 0NN, UK
| | - C E Urch
- Department of Oncology, Hammersmith Hospital Campus, Imperial College London, Du Cane Road, London W12 0NN, UK
| | - S Moser
- Department of Radiology, Hammersmith Hospital, Imperial College, Du Cane Road, London W12 0HS, UK
| | - R Agarwal
- Department of Oncology, Hammersmith Hospital Campus, Imperial College London, Du Cane Road, London W12 0NN, UK
| |
Collapse
|
19
|
Li HK, Linghu EQ. Endoscopic vs. laparoscopic gastrojejunostomy for duodenal obstruction: a randomized study in a porcine model. Endoscopy 2012; 44:634. [PMID: 22638787 DOI: 10.1055/s-0032-1309392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
|
20
|
Shalchi Z, Saso S, Li HK, Rowlandson E, Tennant RC. In response – additional support to high-risk patients can reduce hospital readmissions. Clin Med (Lond) 2010. [DOI: 10.7861/clinmedicine.10-2-202a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
21
|
Abstract
It is a concern that increasing pressure to diagnose, treat and discharge patients rapidly is leading to unacceptably high readmission rates. Readmissions were studied over a two-month period. Patients were identified through the hospital coding system, and electronic discharge summaries provided details of each admission. In total, 69 readmissions were identified, representing 4.34% of medical admissions. Readmitted patients were older than those with single admissions (median age 75 and 71 years, respectively; p < 0.05). Initial length of stay was greater in those patients who would go on to be readmitted (median six days; single admission, two days; p < 0.0001). Seventy-one per cent of readmissions were deemed avoidable, with discharge before conclusive therapy being the leading factor implicated (56%). Readmission is more likely in older patients with complex care needs. Rapid throughput of patients is not associated with readmission. The majority of readmissions can potentially be avoided with judicious medical care.
Collapse
Affiliation(s)
- Z Shalchi
- Acute Medical Assessment Unit, Northwick Park Hospital, North West London Hospitals NHS Trust
| | - S Saso
- Acute Medical Assessment Unit, Northwick Park Hospital, North West London Hospitals NHS Trust
| | - HK Li
- Acute Medical Assessment Unit, Northwick Park Hospital, North West London Hospitals NHS Trust
| | - E Rowlandson
- Acute Medical Assessment Unit, Northwick Park Hospital, North West London Hospitals NHS Trust
| | - RC Tennant
- Acute Medical Assessment Unit, Northwick Park Hospital, North West London Hospitals NHS Trust
| |
Collapse
|
22
|
Li HK. [Malaria survillance in Sance County, Guizhou Province during 1998-9]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2003; 19:61. [PMID: 12572033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
|
23
|
Zhang ZY, Yang CL, Li HK. [Clinical analysis of 70 cases of cysticercosis]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2003; 18:332. [PMID: 12567604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
|
24
|
Zhao GZ, Li HK, Liu Y, Mu W. [Study of the charge transfer reaction between clotrimazolum and alizarin red]. Guang Pu Xue Yu Guang Pu Fen Xi 2001; 21:733-734. [PMID: 12945348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
The charge transfer reaction between clotrimazolum and alizarin red was studied spectrophotometrically. The reaction was achieved with good results in water-acetone solution. The apparent molar absorptivity is 8.7 x 10(3) L.mol-1.cm-1 at 525 nm. The Beer's law was obeyed in the range of 0-100 micrograms.mL-1 of clotrimazolum. The composition of the complex is 1:1. The proposed method has been applied successfully to the determination of clotrimazolum tablets.
Collapse
Affiliation(s)
- G Z Zhao
- Jinzhou Medical College, Jinzhou 121000, China
| | | | | | | |
Collapse
|
25
|
Yu D, Wang ZH, Cheng SB, Li HK, Chan HB, Chew EC. The effect of arsenic trioxide on the expression of Hsc and HNF4 in nuclear matrix proteins in HepG2 cells. Anticancer Res 2001; 21:2553-9. [PMID: 11724321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
Anticancer agents interfere with the proliferation and survival of tumor cells by a variety of mechanisms. An important factor in the development of a cytotoxic effect by certain anticancer agents is the localization of drug-induced lesions within the cell nucleus. Drug-target interactions at the level of nuclear matrix (NM) may be critical events in the induction of cell death by some of these agents. Arsenic trioxide (As2O3) was identified as a very potent anti-leukemic agent by inducing apoptosis. The present study shows that As2O3 significantly inhibits the growth of hepatoblastoma cell line, HepG2, changes the composition of nuclear matrix proteins and reduces the expression of Hsc 70 and HNF4 in HepG2, which in turn initiate a cascade of events that compromise multiple nuclear functions and, ultimately, cell survival.
Collapse
Affiliation(s)
- D Yu
- Department of Surgery, Shenzhen Central Hospital, China
| | | | | | | | | | | |
Collapse
|
26
|
Wang ZH, Yu D, Li HK, Chow VW, Ng CC, Chan HB, Cheng SB, Chew EC. Alteration of nuclear matrix protein composition of neuroblastoma cells after arsenic trioxide treatment. Anticancer Res 2001; 21:493-8. [PMID: 11299786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
The aims of the present study were to assess the effects of arsenic trioxide on the nuclear matrix protein profiles of mouse neuroblastoma cells. Arsenic trioxide induces apoptosis of acute promyelocytic leukemia cells. Our results demonstrated that 2 microM As2O3 could significantly inhibit the growth of Neuro-2a cells. As early as 24 hours after As2O3 treatment, we began to observe the alteration of nuclear matrix proteins and apoptosis in tumor cells by TUNEL assay but not by DNA ladder. An increase expression of Hsc in nuclear matrix proteins of 2 microM As2O3 treated cells was also noted. Our results also showed that before a mass range of apoptosis occurred, the composition of nuclear matrix proteins had altered. Hence the alteration of nuclear matrix proteins, such as increased expression of Hsc, may be a sensitive indicator for the detection of early apoptosis.
Collapse
Affiliation(s)
- Z H Wang
- Department of Anatomy, Chinese University of Hong Kong, China
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Abstract
OBJECTIVES Glaucoma is a major cause of blindness. More than 80,000 Americans suffer permanent vision loss from the disease. Widespread screening is fundamental in limiting the incidence of glaucoma-associated blindness. This pilot study explored the use of stereo digital images taken at a primary care center for telemedicine review by an off-site specialist as a means of screening for glaucoma. MATERIALS AND METHODS Thirty-two diabetic patients were screened at a family medicine clinic. None had previously been diagnosed with glaucoma. A senior optometry student took stereoscopic digital and 35-mm optic disc photographs with a nonmydriatic retinal camera. The digital images were forwarded to a remote ophthalmologist for review. The conventional color stereo slide pairs of the same eyes were subsequently reviewed for comparison. Agreement on signs of glaucomatous disc changes between the two imaging systems was analyzed. RESULTS Twenty-six of 32 eyes' digital and 35-mm photographs were analyzed. Six of 32 eyes (18.8%) could not be compared due to lack of matching 35-mm slides or digital images. Out of 26 eyes, lamina cribosa visibility was undeterminable in 8 eyes' digital images and 3 other eyes' 35-mm slides. Agreement among digital images and 35-mm slides of the remaining eyes was: 100%-vertical elongation, barring of vessels, bayoneting of vessels, and drance hemorrhage; 96.2%-focus notching of rim and rim pallor; 93.3%-lamina cribosa visability; 92. 3%-overpass cupping; 88.5%-focal enlargement; 84.6%-parapapillary halo; 80%-nerve fiber visibility; 65.4%-parapapillary atrophy. Parapapillary halo (p = 0.046) and nerve fiber layer visibility (p = 0.18) were detected on some 35-mm slides but not seen on matching digital views. CONCLUSION Evaluations of cup-to-disc ratio (C/D) using both methods were in general agreement. However, some digital images were noted as too dark for assessing fine glaucomatous disc changes. Stereo digital images taken with a nonmydriatic camera by nonophthalmic photographers is a promising alternative for glaucoma screening in primary care settings. Telemedicine offers efficient communications with off-site glaucoma specialists. A larger study population is necessary to determine the overall effectiveness of using stereo digital imagery and teleophthalmology for glaucoma screening.
Collapse
Affiliation(s)
- H K Li
- Department of Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston, Texas, USA
| | | | | | | | | | | |
Collapse
|
28
|
Hao CF, Wang ZH, Yun JP, Li HK, Ng CC, To KF, Chew-Cheng SB, Chew EC. The measurement of AgNORs in human glioma cells. Anticancer Res 2000; 20:1599-602. [PMID: 10928077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
Sixty gliomas obtained by neurosurgical resections were examined. Paraffin blocks were retrieved from pathological files of the Second Affiliated Hospital in Guangzhou Medical College. The methods of argyrophilic technique for AgNORs staining, and Image Analysis System for measurement of AgNORs were used. Six parameters, which included hcount, count, narea, agnrea, agpern and agperc were used to correlated well with histopathological grades (compared grade 2 & 3, grade 3 & 4, and grade 2 & 4, respectively). We concluded that AgNORs is useful in evaluating proliferative activity and assessing the malignancy of human gliomas. It may also be used as a target for anti-neoplastic drugs in the treatment of gliomas.
Collapse
Affiliation(s)
- C F Hao
- Department of Anatomy, Chinese University of Hong Kong, Shatin, NT, Hong Kong
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Abstract
OBJECTIVE To determine whether the sub-Tenon's parabulbar approach for local anesthesia is a safe and effective choice for posterior segment surgery. DESIGN Prospective, noncomparative case series. PARTICIPANTS Two hundred seventy-six consecutive patients underwent posterior segment surgery at the University of Texas Medical Branch. INTERVENTION Two hundred patients received sub-Tenon's parabulbar anesthesia containing an 11 -ml mixture of 5-ml 2% lidocaine (Xylocaine), 5-ml 0.5% bupivacaine (Marcaine), and 1 ml of 150 hyaluronidase (Wydase) units as primary anesthesia. The method did not involve a separate transcutaneous lid nerve or subconjunctival injection. MAIN OUTCOME MEASURES The proportion of cases receiving supplementation (significant intravenous anesthesia, intraoperative local anesthesia, or both) was estimated. Its relationship to duration of surgery and surgical procedures deemed painful was assessed. Surgery lasting 3 hours or more was considered a long duration. Both scleral buckle and cryotherapy were considered painful procedures. The proportion of cases receiving additional local anesthesia preoperatively was also evaluated. Complications associated with sub-Tenon's parabulbar injection were monitored. RESULTS There were 101 instances of patients receiving additional anesthesia. Nineteen received additional preoperative sub-Tenon's anesthesia, 12 received intraoperative local anesthesia supplementation, and 70 received intravenous medication. Of these 70, 19 required what the authors defined as a significant amount of intravenous medication, three of whom also received intraoperative local anesthesia supplementation. Consequently, 28 of 200 patients (14%; 95% confidence interval: 9.5, 19.6) received supplementation (significant intravenous anesthesia, intraoperative local anesthesia, or both). The proportion of cases receiving supplementation was directly related to duration of surgery. Patients involved in longer cases (51.7% vs. 7.6%; P < 0.001) and those involved in more painful procedures (48.2% vs. 8.7%; P < 0.001) were more likely to receive supplementation. Adjusting for surgery duration, a greater proportion of patients undergoing painful procedures required supplementation (31.3% vs. 0.5% for surgery < 3 hours, P = 0.003; 72.7% vs. 38.9% for surgery > or = 3 hours, P = 0.13). No associated ocular or systemic complications were observed. CONCLUSIONS The results of this large study demonstrate that a single injection of sub-Tenon's anesthesia is relatively safe and effective for achieving local anesthesia during vitrectomies, with or without other intraocular procedures, lasting less than 3 hours. Other types of posterior segment surgery may require supplementation if they are more painful procedures, such as scleral buckle or cryotherapy, or last longer than 3 hours.
Collapse
Affiliation(s)
- H K Li
- Department of Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston 77555-0787, USA
| | | | | | | | | |
Collapse
|
30
|
Abstract
Technology to create and move multimedia medical information is creating alternatives to physically transporting patients and health care professionals. Teletechnology is a physician extender, both supplementing and reinventing traditional health care delivery systems. The potential of comprehensive teleophthalmology is compelling. This article provides a historical perspective of telemedicine, describes various teleophthalmology systems, and surveys teleophthalmology in clinical consultation, research, and education programs around the world. It also discusses basic issues in applying teleophthalmology to public health.
Collapse
Affiliation(s)
- H K Li
- Department of Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston 77555-0787, USA
| |
Collapse
|
31
|
Schiffman JS, Li HK, Tang RA. Telemedicine enters eye care: practical experience. J Ophthalmic Nurs Technol 1998; 17:102-6. [PMID: 9677981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
1. A combination of store-and-forward technology and videoconferencing technology can be used in eye care and other medical specialties. 2. Bandwidth is a rate-limiting factor for obtaining a high-resolution, real-time image. 3. Protocols, clinical and technical, must be used to implement telemedicine in an efficient and high-quality manner.
Collapse
|
32
|
Abstract
A 30-year-old man with bilateral congenital aniridia presented with a subluxated cataract in the right eye. He wore a soft contact lens for aphakic correction in the fellow eye after lensectomy for a subluxated cataract. We performed pars plana lensectomy and vitrectomy with implantation of a transscleral ciliary sulcus fixated posterior chamber intraocular lens in the right eye. Good postoperative visual acuity was obtained.
Collapse
Affiliation(s)
- E I Segal
- Department of Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston 77555, USA
| | | |
Collapse
|
33
|
Abstract
PURPOSE The purpose of the study is to report on a 34-year-old woman with Susac syndrome who presented on two separate occasions with visual acuity loss from a recurrent branch retinal artery occlusion and underwent hyperbaric oxygen treatment with favorable outcome. METHODS Visual acuity was 20/400 in the left eye and count fingers in the right eye after separate occlusive events. The patient underwent hyperbaric oxygen treatment on each occasion of visual acuity loss. The patient subsequently was diagnosed with Susac syndrome (microangiopathy of the retina, brain, and middle ear). The authors present visual fields, photographs, angiograms, and ancillary tests documenting diagnosis and course of treatment. RESULTS On each occasion, visual acuity improved to 20/25 during and was maintained after hyperbaric oxygen treatment. Visual fields showed improvement immediately after treatment. CONCLUSION This is the first report of hyperbaric oxygen treatment for Susac syndrome. Dramatic post-treatment visual field and acuity changes suggest benefit of treatment. Hyperbaric oxygen treatment can be considered a treatment option for visual complications of this syndrome. Susac syndrome should be included in the differential diagnosis of recurrent branch retinal artery occlusion.
Collapse
Affiliation(s)
- H K Li
- Department of Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston 77555, USA
| | | | | |
Collapse
|
34
|
Abstract
We present a rare case of congenital cystic eye associated with holoprosencephaly and tetralogy of Fallot. The orbital cyst was diagnosed preoperatively by computed tomography (CT) scan, and we present the first magnetic resonance imaging (MRI) finding in such a disorder. The orbital cyst expanded over 7 months of follow-up. The cyst was excised in toto and studied by immunohistochemistry, and its content was analyzed biochemically. The patient achieved an acceptable cosmetic result.
Collapse
Affiliation(s)
- A M Mansour
- Department of Ophthalmology, American University of Beirut, Lebanon
| | | |
Collapse
|
35
|
Abstract
Little is known about the natural history of cytomegalovirus (CMV) optic neuritis in the acquired immunodeficiency syndrome. We analyzed the clinical course of CMV optic neuritis in 30 consecutive subjects (35 eyes), and compared the survival of patients with CMV optic neuritis to that of a group having CMV retinitis alone, with both groups matched for ganciclovir therapy. Four untreated eyes had a median final visual acuity of no light perception. The median final visual acuity was 20/100 in treated subjects with a mean follow-up of 6.6 months. Following ganciclovir treatment, 2 eyes showed visual improvement, 17 eyes had unchanged visual acuity, and 12 eyes had marked drop in acuity. Relapse occurred in 4 subjects maintained on single-dose ganciclovir, and was controlled on double-dose ganciclovir. Survival was similar in the group of CMV retinitis alone versus the group of CMV optic neuritis with retinitis. Early recognition and therapy of CMV optic neuritis protects against irreversible visual loss. CMV optic neuritis does not carry a worse prognosis for survival than CMV retinitis alone.
Collapse
Affiliation(s)
- A M Mansor
- Department of Ophthamology, University of Texas Medical Branch, Galveston 77555-0787, USA
| | | |
Collapse
|
36
|
Abstract
Six patients with the acquired immunodeficiency syndrome had frosted periphlebitis associated with large areas of cytomegalovirus retinitis. Following the administration of ganciclovir, periphlebitis resolved within 2-6 weeks concomitant with quieting of cytomegalovirus retinitis. Frosted retinal periphlebitis in the acquired immunodeficiency syndrome is associated with cytomegalovirus retinitis in North America. Medical treatment of cytomegalovirus retinitis leads to resolution of the periphlebitis without the need for systemic corticosteroids.
Collapse
Affiliation(s)
- A M Mansour
- Department of Ophthalmology, University of Texas Medical Branch, Galveston 77555-0787
| | | |
Collapse
|
37
|
Li HK, Ma WZ, Liao J. [Changes in the relaxation and compliance of the left ventricle in cardiomyopathy]. Zhonghua Nei Ke Za Zhi 1989; 28:18-21, 61. [PMID: 2737031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
In order to study the left ventricular diastolic events in cardiomyopathy, carotid pulse tracing, electrocardiogram, phonocardiogram and apexcardiogram with its first derivatives (dA/dt) were simultaneously recorded in 240 normal subjects, 30 patients with dilated cardiomyopathy (DCM) and 44 patients with hypertrophic cardiomyopathy (HCM). Total relaxation time (TRT), total relaxation time index (TRTI), the ratio of A wave to total diastolic amplitude in apexcardiogram (A/D), diastolic amplitude time index (DATI), the ratio of RF wave in apexcardiogram to the total amplitude of apex tracing (F/H) and the variables reflecting the diastolic properties were measured to evaluate the left ventricular relaxation and compliance. Meanwhile, two variables reflecting the contractile ability of the left ventricle were measured in order to compare with the diastolic events. The results demonstrated that in normal subjects relaxation and compliance of the left ventricle showed a tendency of natural "decay" with aging and in patients with DCM and HCM these were significantly decreased, especially in patients with HCM. A/D, which reflects the left ventricular compliance, was increased in patients with HCM as compared with normal subjects (P less than 0.01) and also with patients with DCM. It means that a greater A/D is in favor of the diagnosis of HCM rather than DCM. In addition to abnormal diastolic events, systolic dysfunction, as evidenced by remarkable abnormalities of the contractile variables (PEP/LVET and R-dA/dt.I), was found as well in patients with DCM.
Collapse
|
38
|
Li HK, Ma WZ, Liao J. [Left ventricular relaxation and compliance in normal subjects]. Zhonghua Xin Xue Guan Bing Za Zhi 1988; 16:92-4, 127. [PMID: 3197603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
39
|
|